| Characteristic . | No. (%) . |
|---|---|
| Patient characteristics | |
| Age, y, median (range; IQR) | 62 (23–82; 53–71) |
| Sex | |
| Female | 31 (21.1) |
| Male | 116 (78.9) |
| Hospital admission | |
| Emergency | 134 (91.2) |
| Scheduled | 9 (6.1) |
| Other | 4 (2.7) |
| Infection | |
| Site of primary infection | |
| Respiratory | 96 (65.3) |
| BSI (catheter related) | 16 (10.9) |
| BSI (unknown source) | 23 (15.6) |
| Othera | 12 (8.2) |
| Secondary BSI | 47 (32.0) |
| Polymicrobial infection | 36 (24.5) |
| ICU/ventilation | |
| Any time in ICU | 136 (92.5) |
| Time in ICU, d, median (IQR) | 37 (23.5–51.0) |
| In ICU receiving mechanical ventilation | 116/136 (85.3) |
| Respiratory infection and receiving mechanical ventilation | 82/96 (85.4) |
| Ventilator-associated respiratory infection | |
| VAP | 70/82 (85.4) |
| V-HAP | 11/82 (13.4) |
| Unknownb | 1/82 (1.2) |
| ECMO during hospitalization | 22 (15.0) |
| Patient status and comorbidities | |
| Septic shockc | 70/126 (55.6) |
| COVID-19 during hospitalization | 120 (81.6) |
| Septic shockc and COVID-19 during hospitalization | 58 (39.5) |
| SOFA scored quartile (score range) in ICU, no./No. (median score) | |
| 1 (0–5) | 35/131 (3) |
| 2 (6–9) | 44/131 (8) |
| 3 (10–11) | 32/131 (11) |
| 4 (12–17) | 20/131 (13) |
| Treatment regimen | |
| No. of prior antimicrobial therapiese | |
| 0 | 22 (15.0) |
| 1 | 35 (23.8) |
| 2 | 48 (32.7) |
| 3 | 29 (19.7) |
| 4 | 10 (6.8) |
| ≥5 | 3 (2.0) |
| Prior antimicrobial therapye,f | |
| Colistin | 86 (58.5) |
| Meropenem | 62 (42.2) |
| Tigecycline | 40 (27.2) |
| Piperacillin/tazobactam | 22 (15.0) |
| Ampicillin/sulbactam | 13 (8.8) |
| Reason for discontinuation of prior antimicrobial therapyg | |
| Lack of resolution | 65 (44.2) |
| New resistance | 34 (23.1) |
| Adverse events | 5 (3.4) |
| Other | 19 (12.9) |
| Duration of cefiderocol treatment, d, median (IQR) | 10.0 (8.0–15.0) |
| Cefiderocol administered as monotherapy | 49 (33.3) |
| Septic shockc present | 21/42 (50.0) |
| SOFA scored, median (IQR) | 7.5 (3.0–9.0) |
| Cefiderocol administered as combination therapy | 98 (66.7) |
| Septic shockc present | 49/84 (58.3) |
| SOFA scored, median (IQR) | 9.0 (7.0–11.0) |
| Antibiotic therapy started with cefiderocol administration | |
| Colistin | 27 (18.4) |
| Tigecycline | 22 (15.0) |
| Fosfomycin | 19 (12.9) |
| Meropenem | 3 (2.0) |
| Ampicillin/sulbactam | 2 (1.4) |
| Trimethoprim/sulfamethoxazole | 2 (1.4) |
| Other | 12 (8.2) |
| Characteristic . | No. (%) . |
|---|---|
| Patient characteristics | |
| Age, y, median (range; IQR) | 62 (23–82; 53–71) |
| Sex | |
| Female | 31 (21.1) |
| Male | 116 (78.9) |
| Hospital admission | |
| Emergency | 134 (91.2) |
| Scheduled | 9 (6.1) |
| Other | 4 (2.7) |
| Infection | |
| Site of primary infection | |
| Respiratory | 96 (65.3) |
| BSI (catheter related) | 16 (10.9) |
| BSI (unknown source) | 23 (15.6) |
| Othera | 12 (8.2) |
| Secondary BSI | 47 (32.0) |
| Polymicrobial infection | 36 (24.5) |
| ICU/ventilation | |
| Any time in ICU | 136 (92.5) |
| Time in ICU, d, median (IQR) | 37 (23.5–51.0) |
| In ICU receiving mechanical ventilation | 116/136 (85.3) |
| Respiratory infection and receiving mechanical ventilation | 82/96 (85.4) |
| Ventilator-associated respiratory infection | |
| VAP | 70/82 (85.4) |
| V-HAP | 11/82 (13.4) |
| Unknownb | 1/82 (1.2) |
| ECMO during hospitalization | 22 (15.0) |
| Patient status and comorbidities | |
| Septic shockc | 70/126 (55.6) |
| COVID-19 during hospitalization | 120 (81.6) |
| Septic shockc and COVID-19 during hospitalization | 58 (39.5) |
| SOFA scored quartile (score range) in ICU, no./No. (median score) | |
| 1 (0–5) | 35/131 (3) |
| 2 (6–9) | 44/131 (8) |
| 3 (10–11) | 32/131 (11) |
| 4 (12–17) | 20/131 (13) |
| Treatment regimen | |
| No. of prior antimicrobial therapiese | |
| 0 | 22 (15.0) |
| 1 | 35 (23.8) |
| 2 | 48 (32.7) |
| 3 | 29 (19.7) |
| 4 | 10 (6.8) |
| ≥5 | 3 (2.0) |
| Prior antimicrobial therapye,f | |
| Colistin | 86 (58.5) |
| Meropenem | 62 (42.2) |
| Tigecycline | 40 (27.2) |
| Piperacillin/tazobactam | 22 (15.0) |
| Ampicillin/sulbactam | 13 (8.8) |
| Reason for discontinuation of prior antimicrobial therapyg | |
| Lack of resolution | 65 (44.2) |
| New resistance | 34 (23.1) |
| Adverse events | 5 (3.4) |
| Other | 19 (12.9) |
| Duration of cefiderocol treatment, d, median (IQR) | 10.0 (8.0–15.0) |
| Cefiderocol administered as monotherapy | 49 (33.3) |
| Septic shockc present | 21/42 (50.0) |
| SOFA scored, median (IQR) | 7.5 (3.0–9.0) |
| Cefiderocol administered as combination therapy | 98 (66.7) |
| Septic shockc present | 49/84 (58.3) |
| SOFA scored, median (IQR) | 9.0 (7.0–11.0) |
| Antibiotic therapy started with cefiderocol administration | |
| Colistin | 27 (18.4) |
| Tigecycline | 22 (15.0) |
| Fosfomycin | 19 (12.9) |
| Meropenem | 3 (2.0) |
| Ampicillin/sulbactam | 2 (1.4) |
| Trimethoprim/sulfamethoxazole | 2 (1.4) |
| Other | 12 (8.2) |
Data are from time of cefiderocol initiation and are presented as No. (%) or no./No. (%) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia; V-HAP, ventilated hospital-acquired pneumonia.
Included other (n = 4), skin and soft tissue infections (n = 3), bone or joint infections (n = 2), intra-abdominal infections (n = 2), and urinary tract infection (n = 1).
Unknown time of mechanical ventilation initiation.
Septic shock was defined as a score of 3 or 4 on the cardiovascular domain on the SOFA score.
SOFA scores of 0 were imputed for individual SOFA domains where data were missing, providing a value was recorded for at least 1 of the 6 SOFA domains.
Therapies suitable for gram-negative infections used to treat Acinetobacter spp infections.
Five most frequently used antimicrobials are shown. Patients may have received ≥1 antimicrobial prior to cefiderocol.
Reasons per prior antimicrobial are shown.
| Characteristic . | No. (%) . |
|---|---|
| Patient characteristics | |
| Age, y, median (range; IQR) | 62 (23–82; 53–71) |
| Sex | |
| Female | 31 (21.1) |
| Male | 116 (78.9) |
| Hospital admission | |
| Emergency | 134 (91.2) |
| Scheduled | 9 (6.1) |
| Other | 4 (2.7) |
| Infection | |
| Site of primary infection | |
| Respiratory | 96 (65.3) |
| BSI (catheter related) | 16 (10.9) |
| BSI (unknown source) | 23 (15.6) |
| Othera | 12 (8.2) |
| Secondary BSI | 47 (32.0) |
| Polymicrobial infection | 36 (24.5) |
| ICU/ventilation | |
| Any time in ICU | 136 (92.5) |
| Time in ICU, d, median (IQR) | 37 (23.5–51.0) |
| In ICU receiving mechanical ventilation | 116/136 (85.3) |
| Respiratory infection and receiving mechanical ventilation | 82/96 (85.4) |
| Ventilator-associated respiratory infection | |
| VAP | 70/82 (85.4) |
| V-HAP | 11/82 (13.4) |
| Unknownb | 1/82 (1.2) |
| ECMO during hospitalization | 22 (15.0) |
| Patient status and comorbidities | |
| Septic shockc | 70/126 (55.6) |
| COVID-19 during hospitalization | 120 (81.6) |
| Septic shockc and COVID-19 during hospitalization | 58 (39.5) |
| SOFA scored quartile (score range) in ICU, no./No. (median score) | |
| 1 (0–5) | 35/131 (3) |
| 2 (6–9) | 44/131 (8) |
| 3 (10–11) | 32/131 (11) |
| 4 (12–17) | 20/131 (13) |
| Treatment regimen | |
| No. of prior antimicrobial therapiese | |
| 0 | 22 (15.0) |
| 1 | 35 (23.8) |
| 2 | 48 (32.7) |
| 3 | 29 (19.7) |
| 4 | 10 (6.8) |
| ≥5 | 3 (2.0) |
| Prior antimicrobial therapye,f | |
| Colistin | 86 (58.5) |
| Meropenem | 62 (42.2) |
| Tigecycline | 40 (27.2) |
| Piperacillin/tazobactam | 22 (15.0) |
| Ampicillin/sulbactam | 13 (8.8) |
| Reason for discontinuation of prior antimicrobial therapyg | |
| Lack of resolution | 65 (44.2) |
| New resistance | 34 (23.1) |
| Adverse events | 5 (3.4) |
| Other | 19 (12.9) |
| Duration of cefiderocol treatment, d, median (IQR) | 10.0 (8.0–15.0) |
| Cefiderocol administered as monotherapy | 49 (33.3) |
| Septic shockc present | 21/42 (50.0) |
| SOFA scored, median (IQR) | 7.5 (3.0–9.0) |
| Cefiderocol administered as combination therapy | 98 (66.7) |
| Septic shockc present | 49/84 (58.3) |
| SOFA scored, median (IQR) | 9.0 (7.0–11.0) |
| Antibiotic therapy started with cefiderocol administration | |
| Colistin | 27 (18.4) |
| Tigecycline | 22 (15.0) |
| Fosfomycin | 19 (12.9) |
| Meropenem | 3 (2.0) |
| Ampicillin/sulbactam | 2 (1.4) |
| Trimethoprim/sulfamethoxazole | 2 (1.4) |
| Other | 12 (8.2) |
| Characteristic . | No. (%) . |
|---|---|
| Patient characteristics | |
| Age, y, median (range; IQR) | 62 (23–82; 53–71) |
| Sex | |
| Female | 31 (21.1) |
| Male | 116 (78.9) |
| Hospital admission | |
| Emergency | 134 (91.2) |
| Scheduled | 9 (6.1) |
| Other | 4 (2.7) |
| Infection | |
| Site of primary infection | |
| Respiratory | 96 (65.3) |
| BSI (catheter related) | 16 (10.9) |
| BSI (unknown source) | 23 (15.6) |
| Othera | 12 (8.2) |
| Secondary BSI | 47 (32.0) |
| Polymicrobial infection | 36 (24.5) |
| ICU/ventilation | |
| Any time in ICU | 136 (92.5) |
| Time in ICU, d, median (IQR) | 37 (23.5–51.0) |
| In ICU receiving mechanical ventilation | 116/136 (85.3) |
| Respiratory infection and receiving mechanical ventilation | 82/96 (85.4) |
| Ventilator-associated respiratory infection | |
| VAP | 70/82 (85.4) |
| V-HAP | 11/82 (13.4) |
| Unknownb | 1/82 (1.2) |
| ECMO during hospitalization | 22 (15.0) |
| Patient status and comorbidities | |
| Septic shockc | 70/126 (55.6) |
| COVID-19 during hospitalization | 120 (81.6) |
| Septic shockc and COVID-19 during hospitalization | 58 (39.5) |
| SOFA scored quartile (score range) in ICU, no./No. (median score) | |
| 1 (0–5) | 35/131 (3) |
| 2 (6–9) | 44/131 (8) |
| 3 (10–11) | 32/131 (11) |
| 4 (12–17) | 20/131 (13) |
| Treatment regimen | |
| No. of prior antimicrobial therapiese | |
| 0 | 22 (15.0) |
| 1 | 35 (23.8) |
| 2 | 48 (32.7) |
| 3 | 29 (19.7) |
| 4 | 10 (6.8) |
| ≥5 | 3 (2.0) |
| Prior antimicrobial therapye,f | |
| Colistin | 86 (58.5) |
| Meropenem | 62 (42.2) |
| Tigecycline | 40 (27.2) |
| Piperacillin/tazobactam | 22 (15.0) |
| Ampicillin/sulbactam | 13 (8.8) |
| Reason for discontinuation of prior antimicrobial therapyg | |
| Lack of resolution | 65 (44.2) |
| New resistance | 34 (23.1) |
| Adverse events | 5 (3.4) |
| Other | 19 (12.9) |
| Duration of cefiderocol treatment, d, median (IQR) | 10.0 (8.0–15.0) |
| Cefiderocol administered as monotherapy | 49 (33.3) |
| Septic shockc present | 21/42 (50.0) |
| SOFA scored, median (IQR) | 7.5 (3.0–9.0) |
| Cefiderocol administered as combination therapy | 98 (66.7) |
| Septic shockc present | 49/84 (58.3) |
| SOFA scored, median (IQR) | 9.0 (7.0–11.0) |
| Antibiotic therapy started with cefiderocol administration | |
| Colistin | 27 (18.4) |
| Tigecycline | 22 (15.0) |
| Fosfomycin | 19 (12.9) |
| Meropenem | 3 (2.0) |
| Ampicillin/sulbactam | 2 (1.4) |
| Trimethoprim/sulfamethoxazole | 2 (1.4) |
| Other | 12 (8.2) |
Data are from time of cefiderocol initiation and are presented as No. (%) or no./No. (%) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia; V-HAP, ventilated hospital-acquired pneumonia.
Included other (n = 4), skin and soft tissue infections (n = 3), bone or joint infections (n = 2), intra-abdominal infections (n = 2), and urinary tract infection (n = 1).
Unknown time of mechanical ventilation initiation.
Septic shock was defined as a score of 3 or 4 on the cardiovascular domain on the SOFA score.
SOFA scores of 0 were imputed for individual SOFA domains where data were missing, providing a value was recorded for at least 1 of the 6 SOFA domains.
Therapies suitable for gram-negative infections used to treat Acinetobacter spp infections.
Five most frequently used antimicrobials are shown. Patients may have received ≥1 antimicrobial prior to cefiderocol.
Reasons per prior antimicrobial are shown.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
